Our data revealed that the percentage of cells in CMML patient samples expressing CD116 (GMRα) was significantly higher in the total MNC population compared to control, and this was most pronounced in the CD34+ progenitor subpopulation (89.7 ± 1.6 vs. 50.3 ± 2.7%; P = 0.000003) (Fig 3C and 3D). This evidence concerns the gene CD34 and chronic myelomonocytic leukemia.